Table 2. Clinical characteristics and treatment outcomes of patients (N = 51)

Characteristic Number (≼) Diagnosis type 13 (25.5) Pre-existing cancer 32 (62.7) Relapsed/refractory disease 6 (11.8) Disease status at presentation at the KHCC Remission 28 (55) Relapse/refractory/progressive requiring therapy 23 (45) SEER stage In situ 0 (0) Localized 12 (24) Regional 3 (6) Distant* 35 (70) Diagnosis category Histiocytic disorders 4 (7.8) Acute leukaemia 20 (39 Solid tumours 11 (21.6) Retinoblastoma 3 (5.9) Central nervous system tumours 7 (13.7) Lymphomas 5 (9.8) Other (Non-cancer)† 1 (2) Type of therapy* Steroids 9 (17.6) Chemotherapy 32 (62.7) Radiotherapy 3 (5.8) Surgery 13 (25.5) No therapy 36 (70.6) Off therapy 36	patients (N = 51)	
New cancer diagnosis 13 (25.5)	Characteristic	Number (%)
Pre-existing cancer 32 (62.7)	Diagnosis type	
Relapsed/refractory disease 6 (11.8) Disease status at presentation at the KHCC Remission 28 (55) Relapse/refractory/progressive requiring therapy 23 (45) SEER stage In situ 0 (0) Localized 12 (24) Regional 3 (6) Distant* 35 (70) Diagnosis category Histiocytic disorders 4 (7.8) Acute leukaemia 20 (39) Solid tumours 11 (21.6) Retinoblastoma 3 (5.9) Central nervous system tumours 7 (13.7) Lymphomas 5 (9.8) Other (Non-cancer)† 1 (2) Type of therapy* Steroids 9 (17.6) Chemotherapy 3 (5.8) Surgery 13 (25.5) No therapy 13 (25.5) No therapy 36 (70.6) Off therapy 15 (29.4) Disease status at last follow-up In remission 13 (29.4) Patien	New cancer diagnosis	13 (25.5)
Disease status at presentation at the KHCC Remission 28 (55) Relapse/refractory/progressive requiring therapy 23 (45) SEER stage In situ 0 (0) Localized 12 (24) Regional 3 (6) Distant* 35 (70) Diagnosis category Histiocytic disorders 4 (7.8) Acute leukaemia 20 (39) Solid tumours 11 (21.6) Retinoblastoma 3 (5.9) Central nervous system tumours 7 (13.7) Lymphomas 5 (9.8) Other (Non-cancer)† 1 (2) Type of therapy* Steroids 9 (17.6) Chemotherapy 32 (62.7) Radiotherapy 3 (5.8) Surgery 13 (25.5) No therapy 11 (21.6) Therapy status at KHCC On therapy 36 (70.6) Off therapy 15 (29.4) Disease status at last follow-up In remission 35 (68.6) Not in remission 1	Pre-existing cancer	32 (62.7)
Remission 28 (55) Relapse/refractory/progressive requiring therapy 23 (45) SEER stage In situ 0 (0) Localized 12 (24) Regional 3 (6) Distant* 35 (70) Diagnosis category Histiocytic disorders 4 (7.8) Acute leukaemia 20 (39) Solid tumours 11 (21.6) Retinoblastoma 3 (5.9) Central nervous system tumours 7 (13.7) Lymphomas 5 (9.8) Other (Non-cancer)† 1 (2) Type of therapy* Steroids 9 (17.6) Chemotherapy 32 (62.7) Radiotherapy 3 (5.8) Surgery 13 (25.5) No therapy 10 (21.6) Therapy status at KHCC On therapy 15 (29.4) Disease status at last follow-up In remission 35 (68.6) Not in remission 13 (29.4) Patient status at last follow-up Alive 49 (96)	Relapsed/refractory disease	6 (11.8)
Relapse/refractory/progressive requiring therapy 23 (45)	Disease status at presentation at the KHCC	
In situ	Remission	28 (55)
In situ 0 (0) Localized 12 (24) Regional 3 (6) Distant* 35 (70) Diagnosis category Histiocytic disorders 4 (7.8) Acute leukaemia 20 (39) Solid tumours 11 (21.6) Retinoblastoma 3 (5.9) Central nervous system tumours 7 (13.7) Lymphomas 5 (9.8) Other (Non-cancer)† 1 (2) Type of therapy* Steroids 9 (17.6) Chemotherapy 32 (62.7) Radiotherapy 35 (5.8) Surgery 13 (25.5) No therapy 11 (21.6) Therapy status at KHCC On therapy 36 (70.6) Off therapy 15 (29.4) Disease status at last follow-up In remission 35 (68.6) Not in remission 13 (29.4) Patient status at last follow-up Alive 49 (96)	Relapse/refractory/progressive requiring therapy	23 (45)
Localized 12 (24) Regional 3 (6) Distant* 35 (70) Diagnosis category Histiocytic disorders 4 (7.8) Acute leukaemia 20 (39 Solid tumours 11 (21.6) Retinoblastoma 3 (5.9) Central nervous system tumours 7 (13.7) Lymphomas 5 (9.8) Other (Non-cancer)† 1 (2) Type of therapy* Steroids 9 (17.6) Chemotherapy 32 (62.7) Radiotherapy 3 (5.8) Surgery 13 (25.5) No therapy 11 (21.6) Therapy status at KHCC On therapy 36 (70.6) Off therapy 15 (29.4) Disease status at last follow-up In remission 35 (68.6) Not in remission 13 (29.4) Patient status at last follow-up Alive 49 (96)	SEER stage	
Regional 3 (6) Distant* 35 (70) Diagnosis category 4 (7.8) Acute leukaemia 20 (39) Solid tumours 11 (21.6) Retinoblastoma 3 (5.9) Central nervous system tumours 7 (13.7) Lymphomas 5 (9.8) Other (Non-cancer)† 1 (2) Type of therapy* Steroids 9 (17.6) Chemotherapy 32 (62.7) Radiotherapy 3 (5.8) Surgery 13 (25.5) No therapy 11 (21.6) Therapy status at KHCC On therapy 36 (70.6) Off therapy 15 (29.4) Disease status at last follow-up In remission 35 (68.6) Not in remission 13 (29.4) Patient status at last follow-up Alive 49 (96)	In situ	0 (0)
Distant* 35 (70) Diagnosis category 4 (7.8) Acute leukaemia 20 (39) Solid tumours 11 (21.6) Retinoblastoma 3 (5.9) Central nervous system tumours 7 (13.7) Lymphomas 5 (9.8) Other (Non-cancer)† 1 (2) Type of therapy* 32 (62.7) Steroids 9 (17.6) Chemotherapy 32 (62.7) Radiotherapy 3 (5.8) Surgery 13 (25.5) No therapy 11 (21.6) Therapy status at KHCC On therapy Off therapy 36 (70.6) Off therapy 15 (29.4) Disease status at last follow-up 35 (68.6) Not in remission 35 (68.6) Not in remission 13 (29.4) Patient status at last follow-up 49 (96)	Localized	12 (24)
Diagnosis category	Regional	3 (6)
Histiocytic disorders	Distant*	35 (70)
Acute leukaemia 20 (39 Solid tumours II (21.6) Retinoblastoma 3 (5.9) Central nervous system tumours 7 (13.7) Lymphomas 5 (9.8) Other (Non-cancer)† 1 (2) Type of therapy* Steroids 9 (17.6) Chemotherapy 32 (62.7) Radiotherapy 3 (5.8) Surgery 13 (25.5) No therapy tatus at KHCC On therapy 36 (70.6) Off therapy 15 (29.4) Disease status at last follow-up In remission 35 (68.6) Not in remission 13 (29.4) Patient status at last follow-up Alive 49 (96)	Diagnosis category	
Solid tumours	Histiocytic disorders	4 (7.8)
Retinoblastoma 3 (5.9) Central nervous system tumours 7 (13.7) Lymphomas 5 (9.8) Other (Non-cancer)† 1 (2) Type of therapy* Steroids 9 (17.6) Chemotherapy 32 (62.7) Radiotherapy 3 (5.8) Surgery 13 (25.5) No therapy 11 (21.6) Therapy status at KHCC On therapy 36 (70.6) Off therapy 15 (29.4) Disease status at last follow-up In remission 35 (68.6) Not in remission 13 (29.4) Patient status at last follow-up Alive 49 (96)	Acute leukaemia	20 (39
Central nervous system tumours 7 (13.7) Lymphomas 5 (9.8) Other (Non-cancer)† 1 (2) Type of therapy* Steroids 9 (17.6) Chemotherapy 32 (62.7) Radiotherapy 3 (5.8) Surgery 13 (25.5) No therapy 11 (21.6) Therapy status at KHCC On therapy 36 (70.6) Off therapy 15 (29.4) Disease status at last follow-up In remission 35 (68.6) Not in remission 13 (29.4) Patient status at last follow-up Alive 49 (96)	Solid tumours	11 (21.6)
Lymphomas 5 (9.8) Other (Non-cancer)† 1 (2) Type of therapy* Steroids 9 (17.6) Chemotherapy 32 (62.7) Radiotherapy 3 (5.8) Surgery 13 (25.5) No therapy 11 (21.6) Therapy status at KHCC On therapy 36 (70.6) Off therapy 15 (29.4) Disease status at last follow-up In remission 35 (68.6) Not in remission 13 (29.4) Patient status at last follow-up Alive 49 (96)	Retinoblastoma	3 (5-9)
Other (Non-cancer)† 1 (2) Type of therapy* Steroids 9 (17.6) Chemotherapy 32 (62.7) Radiotherapy 3 (5.8) Surgery 13 (25.5) No therapy 11 (21.6) Therapy status at KHCC On therapy 36 (70.6) Off therapy 15 (29.4) Disease status at last follow-up In remission 35 (68.6) Not in remission 13 (29.4) Patient status at last follow-up Alive 49 (96)	Central nervous system tumours	7 (13.7)
Type of therapy ² 9 (17.6) Chemotherapy 32 (62.7) Radiotherapy 3 (5.8) Surgery 13 (25.5) No therapy 11 (21.6) Therapy status at KHCC On therapy 36 (70.6) Off therapy 15 (29.4) Disease status at last follow-up In remission 35 (68.6) Not in remission 13 (29.4) Patient status at last follow-up Alive 49 (96)	Lymphomas	5 (9.8)
Steroids 9 (17.6) Chemotherapy 32 (62.7) Radiotherapy 3 (5.8) Surgery 13 (25.5) No therapy 11 (21.6) Therapy status at KHCC On therapy 36 (70.6) Off therapy 15 (29.4) Disease status at last follow-up In remission 35 (68.6) Not in remission 13 (29.4) Patient status at last follow-up Alive 49 (96)	Other (Non-cancer)†	1(2)
Chemotherapy 32 (62.7) Radiotherapy 3 (5.8) Surgery 13 (25.5) No therapy 11 (21.6) Therapy status at KHCC On therapy 36 (70.6) Off therapy 15 (29.4) Disease status at last follow-up In remission 35 (68.6) Not in remission 13 (29.4) Patient status at last follow-up Alive 49 (96)	Type of therapy ^t	
Radiotherapy 3 (5.8) Surgery 13 (25.5) No therapy 11 (21.6) Therapy status at KHCC On therapy 36 (70.6) Off therapy 15 (29.4) Disease status at last follow-up In remission 35 (68.6) Not in remission 13 (29.4) Patient status at last follow-up Alive 49 (96)	Steroids	9 (17.6)
Surgery 13 (25.5) No therapy 11 (21.6) Therapy status at KHCC On therapy 36 (70.6) Off therapy 15 (29.4) Disease status at last follow-up In remission 35 (68.6) Not in remission 13 (29.4) Patient status at last follow-up Alive 49 (96)	Chemotherapy	32 (62.7)
No therapy 11 (21.6) Therapy status at KHCC On therapy 36 (70.6) Off therapy 15 (29.4) Disease status at last follow-up In remission 35 (68.6) Not in remission 13 (29.4) Patient status at last follow-up Alive 49 (96)	Radiotherapy	3 (5.8)
Therapy status at KHCC On therapy 36 (70.6) Off therapy 15 (29.4) Disease status at last follow-up In remission 35 (68.6) Not in remission 13 (29.4) Patient status at last follow-up Alive 49 (96)	Surgery	13 (25.5)
On therapy 36 (70.6) Off therapy 15 (29.4) Disease status at last follow-up In remission 35 (68.6) Not in remission 13 (29.4) Patient status at last follow-up Alive 49 (96)	No therapy	11 (21.6)
Off therapy 15 (29.4) Disease status at last follow-up 35 (68.6) Not in remission 13 (29.4) Patient status at last follow-up 49 (96)	Therapy status at KHCC	
Disease status at last follow-up In remission 35 (68.6) Not in remission 13 (29.4) Patient status at last follow-up Alive 49 (96)	On therapy	36 (70.6)
In remission 35 (68.6) Not in remission 13 (29.4) Patient status at last follow-up 49 (96)	Off therapy	15 (29.4)
Not in remission 13 (29.4) Patient status at last follow-up Alive 49 (96)	Disease status at last follow-up	
Patient status at last follow-up Alive 49 (96)	In remission	35 (68.6)
Alive 49 (96)	Not in remission	13 (29.4)
	Patient status at last follow-up	
Dead 2 (4)	Alive	49 (96)
	Dead	2 (4)

^{*}Non-cancer case is excluded from SEER staging

 $[\]dagger$ These data include patients who received more than one type of treatment or a combination of treatments

[‡]Leukaemia is included in distant SEER staging

KHCC = King Hussein Cancer Center; SEER = surveillance, epidemiology and end results